Key Takeaways:
Entrada Therapeutics (Nasdaq: TRDA) announced its Duchenne muscular dystrophy candidate, ENTR-601-44, produced a statistically significant improvement in muscle function in a Phase 1/2 trial, a key early win for its genetic medicine platform. The drug, designed for patients with mutations amenable to exon 44 skipping, showed a favorable safety profile and early signs of clinical efficacy at its lowest dose.
“The first dosing cohort readout from ELEVATE-44-201 is a major step forward, showing that ENTR-601-44 has a strong safety profile and is driving important, clinically meaningful and potentially differentiated early functional benefits,” Dipal Doshi, Chief Executive Officer at Entrada Therapeutics, said. “We were very encouraged to see that the Cohort 1 data delivered statistically significant improvement in Time to Rise velocity.”
The initial cohort of eight boys, aged six to 17, received three 6 mg/kg doses of the drug or a placebo. Treated participants showed an improvement in Time to Rise (TTR) velocity that was 3.5 times higher than the minimal clinically important difference threshold. The trial also met its primary safety objective, with no serious adverse events or discontinuations. Dystrophin, the key protein missing in Duchenne patients, increased by a mean of 2.36 percentage points from a baseline of 4.00 percent.
The results position Entrada to accelerate development, de-risking a key asset in its neuromuscular pipeline. With a cash runway into the third quarter of 2027, the company is well-funded to advance its Duchenne franchise, which also includes candidates for other exon-skipping amenable mutations. The positive data provides validation for Entrada’s Endosomal Escape Vehicle (EEV) platform, which aims to deliver oligonucleotide therapies to previously inaccessible intracellular targets.
The study noted that drug plasma concentration in the pediatric cohort was lower than expected compared to adult healthy volunteers, a finding consistent with recent non-human primate studies. This observation gives the company confidence that a higher dose will lead to greater efficacy.
Consequently, Entrada has already begun dosing a second cohort at 12 mg/kg, double the initial dose. The company’s pharmacokinetic modeling predicts this will result in a significant increase in plasma exposure, leading to higher dystrophin production and enhanced muscle function.
“For those living with Duchenne, a therapy that could lead to both near- and long-term improvements in functional outcomes would be an important breakthrough,” said Dr. Laurent Servais, a professor at the University of Oxford and the study's principal investigator.
Data from the 12 mg/kg cohort and the open-label extension for the first cohort are both expected by the end of 2026. The company is also planning a third cohort at a dose of up to 18 mg/kg.
Alongside the clinical update, Entrada reported a net loss of $39.7 million for the first quarter of 2026. Research and development expenses were $33.1 million, an increase from $32.1 million in the same period last year, driven by the advancing Duchenne programs. The company ended the quarter with $254.9 million in cash, cash equivalents, and marketable securities, which it states is sufficient to fund operations into the third quarter of 2027.
This article is for informational purposes only and does not constitute investment advice.
